4.38 USD
+0.17 (+4.04%)
Taking everything into account, MOLN scores 2 out of 10 in our fundamental rating. MOLN was compared to 530 industry peers in the Biotechnology industry. MOLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MOLN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year MOLN has reported negative net income.
In the past year MOLN has reported a negative cash flow from operations.
In the past 5 years MOLN reported 4 times negative net income.
MOLN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -48.19%, MOLN perfoms like the industry average, outperforming 52.45% of the companies in the same industry.
MOLN's Return On Equity of -56.57% is fine compared to the rest of the industry. MOLN outperforms 63.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.19% | ||
| ROE | -56.57% | ||
| ROIC | N/A |
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MOLN has a Gross Margin of 99.80%. This is amongst the best in the industry. MOLN outperforms 99.06% of its industry peers.
In the last couple of years the Gross Margin of MOLN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MOLN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
2. Health
2.1 Basic Checks
MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MOLN has more shares outstanding
The number of shares outstanding for MOLN has been increased compared to 5 years ago.
MOLN has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.10, we must say that MOLN is in the distress zone and has some risk of bankruptcy.
MOLN has a Altman-Z score of 0.10. This is in the better half of the industry: MOLN outperforms 60.75% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MOLN is not too dependend on debt financing.
MOLN has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: MOLN outperforms 48.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.1 |
ROIC/WACCN/A
WACC4.88%
2.3 Liquidity
A Current Ratio of 9.28 indicates that MOLN has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.28, MOLN is doing good in the industry, outperforming 79.43% of the companies in the same industry.
MOLN has a Quick Ratio of 9.28. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MOLN (9.28) is better than 79.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.28 | ||
| Quick Ratio | 9.28 |
3. Growth
3.1 Past
MOLN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.05%, which is quite good.
The Revenue for MOLN has decreased by -29.38% in the past year. This is quite bad
Measured over the past years, MOLN shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)16.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, MOLN will show a decrease in Earnings Per Share. The EPS will decrease by -4.18% on average per year.
Based on estimates for the next years, MOLN will show a very strong growth in Revenue. The Revenue will grow by 97.69% on average per year.
EPS Next Y6.91%
EPS Next 2Y4.57%
EPS Next 3Y19.94%
EPS Next 5Y-4.18%
Revenue Next Year-83.33%
Revenue Next 2Y35.4%
Revenue Next 3Y108.01%
Revenue Next 5Y97.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MOLN. In the last year negative earnings were reported.
Also next year MOLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MOLN's earnings are expected to grow with 19.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.57%
EPS Next 3Y19.94%
5. Dividend
5.1 Amount
No dividends for MOLN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:MOLN (1/6/2026, 3:40:48 PM)
4.38
+0.17 (+4.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners43.98%
Inst Owner Change0%
Ins Owners4%
Ins Owner ChangeN/A
Market Cap163.81M
Revenue(TTM)4.97M
Net Income(TTM)-54.04M
Analysts82.22
Price Target13.29 (203.42%)
Short Float %0.07%
Short Ratio3.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-2.46%
EPS NY rev (3m)2.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.33%
Revenue NY rev (3m)-33.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 26.13 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.36 | ||
| P/tB | 1.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.92
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.8
OCFYN/A
SpS0.17
BVpS3.22
TBVpS3.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.19% | ||
| ROE | -56.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.8% | ||
| FCFM | N/A |
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 32.33% | ||
| Cap/Sales | 14.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.28 | ||
| Quick Ratio | 9.28 | ||
| Altman-Z | 0.1 |
F-Score3
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)41.08%
Cap/Depr(5y)46.5%
Cap/Sales(3y)8.93%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y6.91%
EPS Next 2Y4.57%
EPS Next 3Y19.94%
EPS Next 5Y-4.18%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-83.33%
Revenue Next 2Y35.4%
Revenue Next 3Y108.01%
Revenue Next 5Y97.69%
EBIT growth 1Y-0.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.85%
EBIT Next 3Y23.24%
EBIT Next 5YN/A
FCF growth 1Y7.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.95%
OCF growth 3YN/A
OCF growth 5YN/A
MOLECULAR PARTNERS AG -ADR / MOLN FAQ
What is the ChartMill fundamental rating of MOLECULAR PARTNERS AG -ADR (MOLN) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MOLN.
What is the valuation status for MOLN stock?
ChartMill assigns a valuation rating of 0 / 10 to MOLECULAR PARTNERS AG -ADR (MOLN). This can be considered as Overvalued.
Can you provide the profitability details for MOLECULAR PARTNERS AG -ADR?
MOLECULAR PARTNERS AG -ADR (MOLN) has a profitability rating of 2 / 10.
What is the financial health of MOLECULAR PARTNERS AG -ADR (MOLN) stock?
The financial health rating of MOLECULAR PARTNERS AG -ADR (MOLN) is 4 / 10.
Can you provide the expected EPS growth for MOLN stock?
The Earnings per Share (EPS) of MOLECULAR PARTNERS AG -ADR (MOLN) is expected to grow by 6.91% in the next year.